NorthSea Therapeutics B.V.
  • Home
  • About
  • Team
  • Presentations
  • Pipeline
  • News
  • Publications
  • Contact
Select Page

Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

12 Apr 2018 | News

Late breaker EASL Icosabutate, a structurally engineered fatty acid, displays optimised phamacokinetics for targeting both metabolic and inflammatory pathways in the liver, both with key relevance for NASH Pre-clinical data show broad and powerful pharmacodynamic...

NorthSea Therapeutics secures €25 million funding for clinical development of promising NASH drug

12 Dec 2017 | News

Lead drug icosabutate, in-licensed from Pronova BioPharma AS Phase IIb-ready at the end of 2018 Naarden, The Netherlands, 12 December 2017 – NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, announced today the completion of a €25m Series...
Next Entries »

NorthSea Therapeutics

NorthSea Therapeutics is a clinical-stage biotech company developing first-in-class, oral, structurally engineered fatty acid therapeutics.

Contact

E: info@northseatherapeutics.com
T: +31 (0) 35 760 65 05

Address

Paasheuvelweg 25-C6
1105 BP Amsterdam
The Netherlands

© NorthSea Therapeutics B.V.